KOD vs GMAB vs REGN vs ABBV vs CRL

For growth investors, AbbVie Inc.

(ABBV) is the stronger pick with 8. 6% revenue growth year-over-year, versus -82. 7% for Genmab A/S (GMAB). Genmab A/S (GMAB) offers the better valuation at 17. 2x trailing P/E (23. 0x forward), making it the more compelling value choice. Analysts rate Kodiak Sciences Inc. (KOD) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Genmab A/S (GMAB) is the cheapest at 17.

2x versus AbbVie Inc. at 85. 0x. On forward P/E, AbbVie Inc. is actually cheaper at 14. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Kodiak Sciences Inc.

(KOD) delivered a total return of +132. 0%, compared to -46. 6% for Charles River Laboratories International, Inc. (CRL). Over 10 years, the gap is even starker: KOD returned +1920% versus GMAB's +74. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 28β versus Kodiak Sciences Inc. 's 1. 67β — meaning KOD is approximately 503% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AbbVie Inc.

(ABBV) is pulling ahead at 8. 6% versus -82. 7% for Genmab A/S (GMAB). On earnings-per-share growth, the picture is similar: Regeneron Pharmaceuticals, Inc. grew EPS 8. 2% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, REGN leads at 5. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMAB leads at 33. 6% versus 0. 0% for KOD. At the gross margin level — before operating expenses — GMAB leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AbbVie Inc.

(ABBV) trades at 14. 2x forward P/E versus 23. 0x for Genmab A/S — 8. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for KOD: 57. 7% to $64. 67.

In this comparison, ABBV (3.

3% yield), REGN (0. 5% yield) pay a dividend. KOD, GMAB, CRL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 28), 3. 3% yield, +293. 8% 10Y return). Both have compounded well over 10 years (ABBV: +293. 8%, CRL: +114. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KOD is a small-cap quality compounder stock; GMAB is a mid-cap deep-value stock; REGN is a mid-cap deep-value stock; ABBV is a large-cap income-oriented stock; CRL is a small-cap quality compounder stock. ABBV pays a dividend while KOD, GMAB, REGN, CRL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.